Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 7/20 | 0.54 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.42 |
| ▸ | HPGD | P15428 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.41 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.41 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.41 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.41 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4890983 | 0.87 | PDE3B (0.54) | HSD17B10PDE3BPDE3AKDM4EHPGD | |
| SCHEMBL4891258 | 0.83 | KDM4E (0.42) | HSD17B10KDM4EHPGDALDH1A1MAPT | |
| Resequinil SCHEMBL29375531 | 0.82 | PIK3CD (0.57) | HSD17B10PDE3BPDE3AKDM4EHPGD | |
| Resequinil SCHEMBL677466 | 0.82 | PIK3CD (0.57) | HSD17B10PDE3BPDE3AKDM4EHPGD | |
| SCHEMBL4887340 | 0.77 | PDE3B (0.45) | HSD17B10PDE3BPDE3AKDM4EHPGD | |
| SCHEMBL6432302 | 0.73 | KDM4E (0.59) | HSD17B10PDE3BPDE3AKDM4EHPGD | |
| SCHEMBL4888744 | 0.70 | MAPT (0.51) | HSD17B10PDE3BPDE3AKDM4EHPGD | |
| SCHEMBL678532 | 0.70 | PIK3CD (0.55) | HSD17B10KDM4EHPGDALDH1A1MAPT | |
| SCHEMBL10809294 | 0.68 | PDE3B (0.57) | HSD17B10PDE3BPDE3AKDM4EHPGD | |
| SCHEMBL10806836 | 0.68 | PDE3A (0.57) | PDE3BPDE3AKDM4EHPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275075-A1 | Medicine Comprising a Combination of an Acetylcholinesterase Inhibitor and a 5-Substituted-3-Oxadiazolyl-1,6-Naphthyridin-2(1H)-One Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-11-06 | — | — | US | claimed |
| EP-1736155-A1 | MEDICINE COMPRISING COMBINATION OF ACETYLCHOLINE ESTERASE INHIBITOR AND 5-SUBSTITUTED 3-OXADIAZOLYL-1,6-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-27 | — | — | EP | claimed |
| EP-1010699-B1 | 5-SUBSTITUTED-3-OXADIAZOLYL-1,6-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVES | DAINIPPON PHARMACEUTICAL CO (JP) | 2005-06-15 | — | — | EP | claimed |
| US-6743803-B2 | SUCH AS ALZHEIMER'S DISEASE AND SCHIZOPHRENIA DUE TO HYPOFUNCTION OF GLUTAMIC ACID RECEPTOR; 5-SUBSTITUTED-3-OXADIAZOLYL-1,6-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVES | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-06-01 | — | — | US | claimed |
| US-20030166673-A1 | Medicines for the prevention and treatment of neurodegenerative diseases | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2003-09-04 | — | — | US | claimed |
| EP-1295883-A1 | MEDICINES FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | Dainippon Pharmaceutical Co., Ltd. (JP) | 2003-03-26 | — | — | EP | claimed |
| US-6172079-B1 | BENZODIAZEPINE INVERSE AGONISTS; ALZHEIMER*S DISEASE; ANXIOLYTIC AGENTS, SEDATIVES, MUSCLE RELAXANTS, ANTIEPILEPTIC AGENTS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2001-01-09 | — | — | US | claimed |
| EP-1010699-A1 | 5-SUBSTITUTED-3-OXADIAZOLYL-1,6-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVES | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2000-06-21 | — | — | EP | claimed |
| US-20080275075-A1 | Medicine Comprising a Combination of an Acetylcholinesterase Inhibitor and a 5-Substituted-3-Oxadiazolyl-1,6-Naphthyridin-2(1H)-One Derivative | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-11-06 | — | — | US | disclosed |
| EP-1736155-A1 | MEDICINE COMPRISING COMBINATION OF ACETYLCHOLINE ESTERASE INHIBITOR AND 5-SUBSTITUTED 3-OXADIAZOLYL-1,6-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2006-12-27 | — | — | EP | disclosed |
| EP-1010699-B1 | 5-SUBSTITUTED-3-OXADIAZOLYL-1,6-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVES | DAINIPPON PHARMACEUTICAL CO (JP) | 2005-06-15 | — | — | EP | disclosed |
| US-6743803-B2 | SUCH AS ALZHEIMER'S DISEASE AND SCHIZOPHRENIA DUE TO HYPOFUNCTION OF GLUTAMIC ACID RECEPTOR; 5-SUBSTITUTED-3-OXADIAZOLYL-1,6-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVES | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-06-01 | — | — | US | disclosed |
| US-20030166673-A1 | Medicines for the prevention and treatment of neurodegenerative diseases | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2003-09-04 | — | — | US | disclosed |
| EP-1295883-A1 | MEDICINES FOR THE PREVENTION AND TREATMENT OF NEURODEGENERATIVE DISEASES | Dainippon Pharmaceutical Co., Ltd. (JP) | 2003-03-26 | — | — | EP | disclosed |
| US-6277993-B1 | USEFUL AS A BENZODIAZEPINE INVERSE AGONIST, FOR EXAMPLE, AS PSYCHOANALEPTIC DRUG OR DRUG FOR TREATMENT OF DYSMNESIA IN SENILE DEMENTIA OR ALZHEIMER'S DISEASE | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2001-08-21 | — | — | US | disclosed |
| US-6172079-B1 | BENZODIAZEPINE INVERSE AGONISTS; ALZHEIMER*S DISEASE; ANXIOLYTIC AGENTS, SEDATIVES, MUSCLE RELAXANTS, ANTIEPILEPTIC AGENTS | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2001-01-09 | — | — | US | disclosed |
| EP-1010699-A1 | 5-SUBSTITUTED-3-OXADIAZOLYL-1,6-NAPHTHYRIDIN-2(1H)-ONE DERIVATIVES | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2000-06-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275075-A1 | Medicine Comprising a Combination of an Acetylcholinesterase Inhibitor and a 5-Substituted-3-Oxadiazolyl-1,6-Naphthyridin-2(1H)-One Derivative | ACHE, BCHE, CHAT | HSD17B10 63/4885PDE3B 262/4885PDE3A 323/4885 |
| US-20030166673-A1 | Medicines for the prevention and treatment of neurodegenerative diseases | GRIN1, GRIN2A, GRM2 | HSD17B10 1135/4885PDE3B 2905/4885PDE3A 2663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.